Diagnostic tools: Various tests to diagnose and manage
hepatitis C including various biochemical marker, imaging, liver biopsy for
grading/staging liver disease and HCV RNA (viral load) tests.
·
Biochemical/Imaging
o
181. Ratio Interquartile Range /
Median Value of Liver Stiffness Measurement is a Key Factor of Accuracy of
Transient Elastography (FIBROSCAN®) for the Diagnosis of Liver Fibrosis
o
182. Performance of non-invasive
methods in the assessment of disease severity in routine clinical practice in
patients with chronic hepatitis C
o
184. Comparison of MR elastography,
ultrasound elastography and APRI for the non-invasive assessment of liver
fibrosis
o
185. Fibrotest versus liver biopsy:
An independent multicenter evaluation of performance
o
186. Prospective comparison of two
algorithms combining non invasive tests for staging of liver fibrosis in
chronic hepatitis C
o
1335. European Liver Fibrosis (ELF) panel of
serum markers can predict clinical outcome in a cohort of patients from England
with mixed aetiology chronic liver disease
o
1338. Diagnostic Accuracy of the APRI for
the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review
o
1339. Comparison of reproducibility of
histology, blood tests and Fibroscan for liver fibrosis (updated November 6, 2007)
o
1344. Interobserver Reproducibility of Liver
Stiffness Measurement by Transient Elastography (FIBROSCAN®)
o
1346. The result of liver stiffness
measurement is influenced by the serum bilirubin level
o
1348. Accurate Identification of Liver
Fibrosis Using the Point-Of-Care Continuous 13C Methacetin Breath Test: A
Decision Making Tool in the Treatment of Patients with Chronic HCV Infection
(updated November 6, 2007)
o
1351. Serum levels of sH2a, a secreted form
of the asialoglycoprotein receptor, as a non-invasive sensitive marker for
liver function
o
1355. Can platelet count or APRI be the poor
man’s Transient Elastography in HCV patients?
o
1363. Comparison of two real-time PCR based
assays (RealTime HCV, Cobas TaqMan) with a signal amplification assay (bDNA)
for HCV RNA detection
o
1365. Fibrosis stages determination,
reproducibility and robustness of blood tests for liver fibrosis in chronic
hepatitis C
o
1367. The APRI Can Negatively Predict Cirrhosis
in Patients With Chronic Hepatitis C (HCV) (updated November 6, 2007)
o
1368. Prospective comparison of two
commercial non-invasive fibrosis serum marker panels (FibroSure and FibroSpect
II) during interferon-based combination therapy in chronic HCV genotype 1
o
1369. A practical index (FibroIndex) for the
prediction of significant fibrosis in patients with chronic hepatitis C
·
Biopsy
o
1325. Correlation between liver biopsy and
FibroSURETM during screening for a Phase II study to assess the antifibrotic
activity of Farglitizar in chronic hepatitis C infection
o
1342. Large scale validation of the SAFE
(Sequential Algorithms for Fibrosis Evaluation) biopsy in chronic hepatitis C
(updated November 9, 2007)
·
General
o
1349. Iron overload does not effect the
quantification of fibrosis by Liver Stiffness Measurement
o
1373. Higher Level of Alanine
Aminotransferase Mass in Liver Disease Patients Than Normal Population Measured
by Sandwich ELISA
o
1374. In vivo detection of caspase activity
in patients with chronic hepatitis C as a novel biomarker of disease severity
·
Viral load
o
1299. What is the impact of higher sensitivity
assay on response-guided therapy in hepatitis C virus (HCV)? Comparative
analysis between TaqMan™ and Amplicor™ tests from two large randomized
international trials of PEGASYS® plus COPEGUS®